<DOC>
	<DOCNO>NCT01527513</DOCNO>
	<brief_summary>To evaluate effect eslicarbazepine acetate cognition comparison placebo adjunctive therapy child age 6 16 year old refractory partial-onset seizure .</brief_summary>
	<brief_title>Effects Eslicarbazepine Acetate ( Esl , Bia 2-093 ) Cognitive Function Children With Partial Onset Seizures</brief_title>
	<detailed_description>This 2-part multicentre study approximately 117 patient . Part I study consist 4-week prospective observational baseline period , 12-week double-blind period ( 4-week up-titration 8-week maintenance ) , tapering-off period . After screen visit ( V1 ) , patient enter baseline period . At end baseline period ( V2 ) , eligible patient randomise ratio 2:1 receive double-blind treatment Eslicarbazepine acetate Placebo addition concomitant therapy 1 2 Anti-Epileptic Drugs ( AEDs ) . Concomitant AED therapy keep stable whole study . Initial dose study treatment 10 mg/kg/day . After 2-weeks 10 mg/kg/day , dose up-titrated 20 mg/kg/day ( maximum 1200 mg/day ) . After 2 week 20 mg/kg/day , dose up-titrated 30 mg/kg/day ( maximum 1200 mg/day ) patient receive dose 8 week . If intolerable adverse event ( AEs ) occur , patient down-titrated previous dose ( 1 down-titration step allow ) discontinue . After 8-week maintenance period , study treatment taper 10 mg/kg/day 2 week step . However , patient experience increase seizure frequency ( e.g . 100 % increase vs. baseline ) tapering-off , patient proceed directly open-label part study ( Part II ) . After completion last 2-week 10 mg/kg/day step , patient option enter 1 year open-label treatment ( Part II ) Eslicarbazepine acetate ( 30 mg/kg/day , maximum 1200 mg/day ) , 4 week observational follow-up period .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>At visit 1 ( screen ) , patient must be/have : write informed consent parent legal guardian , applicable , patient ; age 6 16 year , inclusive ; document diagnosis epilepsy least 12 month prior screen ; least 2 partial onset seizures 4 week prior screen despite treatment 1 2 AEDs stable dose regimen ; Intelligence Quotient ( IQ ) least 70 ; current treatment 1 2 AEDs ( except oxcarbazepine , benzodiazepine clobazam vagus nerve stimulation ( VNS ) ) ; except epilepsy , patient judge general good health base medical history , physical examination clinical laboratory test ; opinion investigator , able complete Cognitive Drug Research ( CDR ) test battery ; case girl childbearing potential , patient present serum Bhuman chorionic gonadotropin ( B hCG ) test consistent non gravid state agree remain abstinent use reliable contraception ( use , hormonal contraception must combine barrier method ) start screen continue least poststudy visit ( PSV ) . At visit 2 ( randomisation ) , patient must be/have : least 2 partialonset seizure 4 week baseline period prior randomisation ( documented diary ) ; case girl childbearing potential , patient present urine BhCG test consistent nongravid state ; stable dose regimen concomitant AEDs 4 week baseline period ; diary satisfactorily complete patient his/her caregiver baseline period ; satisfactory compliance study requirement baseline period . At visit 1 ( screen ) , patient must be/have : simple partial seizure motor symptomatology ; primarily generalise seizure ; know rapidly progressive neurological disorder ( progressive brain disease , epilepsy secondary progressive cerebral lesion ) ; occurrence seizure close count accurately ; history status epilepticus cluster seizure ( i.e. , 3 seizure within 30 minute ) within 3 month prior screen ; seizure nonepileptic origin ; LennoxGastaut syndrome ; West syndrome ; major psychiatric disorder ; seizures psychogenic origin within last 2 year ; history schizophrenia suicide attempt ; history attention deficit disorder diseases adversely affect cognitive ability ; currently treat oxcarbazepine , benzodiazepine clobazam ( routine chronic basis ) and/or VNS ; know hypersensitivity carboxamide derivative ( oxcarbazepine carbamazepine ) ; uncontrolled cardiac , renal , hepatic , endocrine , gastrointestinal , metabolic , haematological oncology disorder ; second third degree atrioventricular blockade ; relevant clinical laboratory abnormality ; estimate creatinine clearance ( CLCR ) &lt; 60 mL/min ; pregnancy nursing ; treatment eslicarbazepine acetate previous study ; participation drug clinical trial within last 2 month ; ensure capability perform trial ; condition circumstance , opinion investigator , may compromise patient 's ability comply study protocol . At visit 2 ( randomisation ) , patient must / : â€¢ condition circumstance , opinion investigator , may compromise patient 's ability comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Partial Epilepsy</keyword>
	<keyword>eslicarbazepine acetate</keyword>
	<keyword>Children</keyword>
</DOC>